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Abstract 
Objective: To validate self-reported use of medications for secondary prevention of coronary heart disease (CHD) in a population- 
based health study by comparing self-report with pharmacy dispensing data, and explore different methods for defining medication use 
in prescription databases. 
Study design and setting: Self-reported medication use among participants with CHD ( n = 1483) from the seventh wave of the 
Tromsø Study was linked with the Norwegian Prescription Database (NorPD). Cohen’s kappa, sensitivity, specificity, and positive and 
negative predictive values were calculated, using NorPD as the reference standard. Medication use in NorPD was defined in three ways; 
fixed-time window of 180 days, and legend-time method assuming a daily dose of one dosage unit or one defined daily dose (DDD). 
Results: Kappa-values for antihypertensive drugs, lipid-lowering drugs and acetylsalicylic acid all showed substantial agreement 
(kappa ≥0.61). Validity varied depending on the method used for defining medication use in NorPD. Applying a fixed-time window 
gave higher agreement, positive predictive values and specificity compared with the legend-time methods. 
Conclusion: Self-reported use of medication for secondary prevention of CHD shows high validity when com- 
pared with pharmacy dispensing data. For CHD medications, fixed-time window appears to be the most appropri- 
ate method for defining medication use in prescription databases. © 2021 The Author(s). Published by Elsevier Inc. 
This is an open access article under the CC BY license ( http://creativecommons.org/licenses/by/4.0/ ) 
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What this adds to what is known? What is new? 
Key findings 
• Self-reported use of lipid-lowering drugs, antihy- 
pertensive drugs and acetylsalicylic acid among 
patients with coronary heart disease showed high 
agreement when compared with pharmacy dispens- 
ing data. Using a fixed-time window to define cur- 
rent medication use gave higher agreement, positive 
predictive values and specificity compared with the 
legend-time methods. Abbreviations: ASA, acetylsalicylic acid; CHD, coronary heart dis- 
ease; DDD, defined daily dose; LLD, lipid-lowering drug; NorPD, Nor- 
wegian Prescription Database; NPV, negative predictive value; PPV, pos- 
itive predictive value. 
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( http://creativecommons.org/licenses/by/4.0/ ) • Self-reported medication use for coronary heart dis- 
ease collected with a questionnaire combining pre- 
specified and open-ended questions gives a valid 
measure of medication use. 
• For coronary heart disease medication, a fixed-time 
window is better than legend-time methods in defin- 
ing current use from prescription data. If legend- 
time is used and the prescribed dose is unavailable, 
assuming a daily dose of one dosage unit is a better 
choice than one defined daily dose for these medi- 
cations. ccess article under the CC BY license 













































































What is the implication, what should change 
now? 
• Though a combination of self-report and prescrip- 
tion data classifies medication exposure most accu- 
rately, self-reported information on medication for 
secondary prevention of coronary heart disease has 
adequate validity to be used for epidemiological re- 
search if prescription data is unavailable. 
• When investigating current use of medications for 
coronary heart disease using prescription databases, 
fixed-time window appears to be a more appropriate 
method than the legend-time method. 
1. Introduction 
Medication use is an important factor in many epidemi-
ological studies, either as exposure or outcome. Poor mea-
surement of medication use can lead to over- or underes-
timation of true associations and risks [1] . 
There are several ways to measure medication use,
where self-reported use, e.g. questionnaires or interviews,
and pharmacy dispensing data are common methods. Un-
fortunately, no method provides information about the true
medication exposure. Self-reported use may be biased by
poor recall and underreporting of socially stigmatized med-
ication classes [2 , 3] . Despite being collected objectively
and nondifferentially, dispensing data cannot account for
secondary nonadherence, i.e., dispensed medication is not
necessarily used. It may also be prone to selection bias as
some data sources include only reimbursed medications,
and others are based on claims from selected insurance
companies or pharmacies [4–10] . A few countries, like
the Scandinavian countries, have complete prescription reg-
istries that include all prescription-based medications dis-
pensed from pharmacies [11] . 
Several studies have compared medication use measure-
ments from different data sources [4–10 , 12–17] . Most stud-
ies find good agreement and validity between self-reported
and dispensing data when investigating medications used
for long-term conditions. Results are less consistent for
medications used as needed [9 , 10 , 12 , 13] . Cardiovascular
medications, such as antihypertensive drugs, lipid-lowering
drugs (LLDs) and antiplatelet drugs, are normally used on
a daily basis, and agreement and validity between different
data sources are usually found to be high [4–7 , 9 , 10 , 12–17] .
However, few studies have investigated this in a popu-
lation with established coronary heart disease (CHD) or
compared data from complete prescription registries with
self-reported data from a large population study. 
A methodological concern with prescription registry
data entails defining “current medication use”. The two
most commonly applied methods are fixed-time window
and legend-time duration. Fixed-time window is most fre-
quently applied and defines participants as medication-users if they have been dispensed the medication within a
set time window before an index date [8 , 17] . The legend-
time method uses information from the last prescription
dispensed before the index date to calculate whether the
dispensed medication will last to the index date [8 , 17] .
Some studies have compared the two methods, but no con-
sensus have been reached concerning which is the most
appropriate for defining current medication use [8 , 12 , 18] . 
This study aimed to validate self-reported use of medi-
cations for secondary prevention of CHD in a population-
based health study by comparing self-report with pharmacy
dispensing data using the Norwegian Prescription Database
(NorPD) as the reference standard, and exploring different
methods for defining medication use in NorPD. 
2. Methods 
2.1. The Tromsø study 
The Tromsø Study is a population-based health study
that has been conducted seven times from 1974 to 2016
[19] . The study includes inhabitants in the municipality of
Tromsø, Norway, a town with approximately 73,000 inhab-
itants in 2016. The present study used data collected dur-
ing 2015-16 from the seventh wave of the Tromsø Study
(Tromsø 7), where all inhabitants ≥ 40 years ( n = 32,591)
were invited to participate. The response rate was 65% ( n
= 21,083). 
Participation in Tromsø 7 included answering two ques-
tionnaires, donating blood samples and going through clin-
ical examinations. Most questions about diseases and med-
ication use were posed in questionnaire 1, which could be
answered either on paper or electronically anytime between
invitation and attending the health examination. Links to
the questionnaires can be found at the Tromsø Study’s
webpage [19] . 
2.2. The Norwegian Prescription Database (NorPD) 
NorPD contains complete information about all pre-
scribed medications dispensed from Norwegian pharma-
cies to individuals since January 2004. Medications used
in hospitals/nursing homes and over-the-counter medica-
tions are not included. We included the following vari-
ables from NorPD: date of dispensing and information on
medications dispensed (including Anatomical Therapeutic
Chemical (ATC) code, and number of dosage units and de-
fined daily doses (DDDs) dispensed [20] ). DDD is defined
as “the assumed average maintenance dose per day for a
drug used for its main indication in adults” [20] . 
2.3. Study population 
From Tromsø 7, we included participants reporting es-
tablished CHD ( n = 1483). CHD was defined as reporting
either previous myocardial infarction, present or previous


















































































angina pectoris, previous percutaneous coronary interven-
tion or coronary artery bypass graft surgery. 
2.4. Medications included 
We included medications for secondary prevention
of CHD ( Fig. 1 ), which according to the prevailing
European guidelines in 2015/2016 was acetylsalicylic
acid (ASA), LLDs (mainly statins) and antihypertensive
drugs (angiotensin-converting enzyme (ACE)-inhibitors,
angiotensin receptor blockers (ARBs), beta-blockers,
calcium-channel blockers (CCBs), thiazides and other
antihypertensives) [21] . 
2.5. Defining medication use 
In Tromsø 7, medication use was self-reported through
i) questions about specific medication use and ii) partici-
pants listing the brand names for all medications used reg-
ularly the previous four weeks. We defined users of LLDs
and antihypertensive drugs as participants answering “cur-
rently” to the two specific questions “Do you use, or have
you used cholesterol-lowering drugs? ” and “Do you use,
or have you used blood pressure lowering drugs?”, (re-
sponse alternatives were “currently”, “previously, not now”
and “never used”) and/or listing the brand name of an LLD
or antihypertensive drug, respectively. We defined users
of ASA as participants answering “yes” when asked “If
you have used analgesics and anti-inflammatory medica-
tion regularly in the past year - did you use “Baby” or
low dose acetylsalicylic acid (ASA), i.e. Acetylsalisylsyre ®,
Albyl-E ®, Asasantin Retard ® (75/160 mg per tablet)?”
(response alternatives were “yes” and “no”), or denoting a
brand name for ASA. 
From NorPD, current use was defined by three ap-
proaches; one using a fixed-time window and two us-
ing the legend-time method ( Fig. 2 ). For all approaches,
index date was the day the participants completed the
Tromsø 7 questionnaire. Using a fixed-time window def-
inition, medication-users were participants who had been
dispensed at least one prescription within 180 days before
index date. A sensitivity analysis was performed using time
windows of 90 and 365 days. The legend-time method re-
quires knowledge about the duration of use. As prescribed
daily dose is not available in NorPD, we calculated the
duration supplied assuming the daily dose was equal to:
i) one dosage unit (e.g. tablet, capsule etc.), and ii) one
DDD. In both legend-time approaches, we added 10% to
the duration to account for imperfect adherence before as-
sessing whether the duration of the last dispensation cov-
ered the index date. Sensitivity analyses were performed
by not adding any additional units/DDDs, and by adding
20% additional units/DDDs. 2.6. Statistical analysis 
Data from Tromsø 7 was linked with NorPD data using
the unique national identity number assigned to all citizens
in Norway. NorPD performed the record linkage according
to standard procedures. Agreement between Tromsø 7 and
NorPD was measured by percent observed agreement and
Cohen’s kappa. Kappa-values were interpreted as proposed
by Landis and Koch: poor ( < 0.00), slight (0.00 to 0.20),
fair (0.21 to 0.40), moderate (0.41 to 0.60), substantial
(0.61 to 0.80), or almost perfect (0.81 to 1.00) [22] . 
To determine the validity of self-reported medication
use, we calculated sensitivity and specificity using NorPD
as the reference standard. Positive (PPV) and negative
(NPV) predictive values were also calculated. 
Analyses were conducted applying IBM SPSS 25 for
Windows. Confidence intervals were calculated using Vas-
sarStats [23 , 24] . Results are expressed as proportions and
kappa-values with 95% confidence intervals. 
2.7. Ethics 
The study was approved by the Regional Committee
for Medical and Health Research Ethics of North Norway
(2015/1775) and had an approved Data Protection Impact
Assessment from UiT The Arctic University of Norway.
All participants in the Tromsø Study have given written
informed consent for their data to be used in research. 
3. Results 
In the study population ( n = 1483), 70% were male
and mean age was 68.7 (standard deviation 10.8) years.
Medication use is shown in Table 1 . 
Agreement was substantial for antihypertensive drugs,
LLDs and ASA, with kappa-values ≥0.61 ( Table 2 ). An
exception was for ASA when using either of the legend-
time methods, in which case the kappa-value was 0.60.
The fixed-time window method gave higher agreement than
either of the legend-time methods, both in terms of per-
cent agreement and kappa. For antihypertensive drugs, the
kappa-value showed an almost perfect agreement when us-
ing a fixed-time window. 
Among participants where the two data sources did not
agree, more participants were identified as ASA-users in
NorPD than in Tromsø 7, while the result was opposite for
LLD-users ( Table 2 ). For antihypertensive drugs, more par-
ticipants were identified as users in NorPD than in Tromsø
7 when using a fixed-time window, but opposite when us-
ing the legend-time methods. 
PPV was high for all three main medication classes,
which shows that when participants report using these
medications, the likelihood that they had it dispensed is
high. Highest values were found using fixed-time window,
while legend-time with DDD gave the lowest values. NPV
was high for antihypertensive drugs and LLDs but lower
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Fig. 1. Overview of included ATC-codes and aggregation into medication groups. 
∗When, instead of brand name, the participants in free text reported using medication interpretable as “blood pressure lowering” or “cholesterol 
lowering”, it was registered under the respective medication category. 
Abbreviations: ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; ATC, anatomical therapeutic chemical classification sys- 
tem; CCB, calcium-channel blocker. 
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Fig. 2. The three different methods used to define medication users in NorPD. Index date is the day of questionnaire completion. Using fixed-time 
window, participants were defined as medication-users if they had a medication dispensed ≤180 days before index date. The legend-time methods 
defined a participant as user if the supply of medication most recently dispensed would last past the index date, assuming a daily dosage of either 
one unit (e.g., tablet) or one DDD. Medications A, B and C are in use according to fixed-time window; A and D are in use when applying legend-time 
with one unit a day; A and B are in use applying legend-time with one DDD a day. Medication E is not defined as in use by any of the methods. 
Abbreviations: DDD, defined daily dose; NorPD, Norwegian Prescription Database 
Table 1. Prevalence of use ( n (%)) of medications for secondary prevention of coronary heart disease in Tromsø 7 and the three approaches for 
defining medication use in NorPD ( n = 1483) 
Tromsø 7 NorPD, Fixed-time NorPD, Legend-time, Unit NorPD, Legend-time, DDD 
Antihypertensive drugs 1069 (72.1) 1087 (73.3) 1032 (69.6) 865 (58.3) 
Lipid-lowering drugs 1133 (76.4) 1074 (72.4) 960 (64.7) 928 (62.6) 
Acetylsalicylic acid 980 (66.1) 1098 (74.0) 991 (66.8) 991 (66.8) 





























for ASA. For NPV, the legend-time methods and especially
using DDDs gave the highest values, but the difference be-
tween methods was small. 
Sensitivity was also high for all three main medica-
tion classes. This indicates that a high proportion of those
registered as users in NorPD also self-reported use of
these medications in Tromsø 7. Specificity was lower than
the sensitivity for antihypertensive drugs and LLDs, but
higher for ASA. The specificity was lowest when using
the legend-time methods, and especially with one DDD as
the daily dosage. 
Among the antihypertensive drugs, an almost perfect
agreement was found for angiotensin-converting enzyme
(ACE)-inhibitors, angiotensin receptor blockers (ARBs)
and calcium-channel blockers (CCBs) when using fixed-
time window, while the legend-time methods gave substan-tial to almost perfect agreements ( Table 3 ). The kappa-
values for thiazides showed substantial agreement. For
beta-blockers, agreement was substantial when using fixed-
time window and legend-time method with one unit a
day, and fair with legend-time method with one DDD a
day. For statins, agreement was substantial when using the
fixed-time window method and fair with either legend-time
method. 
Sensitivity analyses showed higher agreement for a 180
days than a 90 days fixed-time window, and the main
analysis (with 10% extra added to the duration) for the
legend-time methods showed higher agreement than no
addition. Using a 365 days fixed-time window or adding
20% to the duration in the legend-time methods gave re-





















Table 2. Self-reported use of antihypertensive drugs, lipid-lowering drugs and acetylsalicylic acid in the Tromsø 7 questionnaire compared with the three approaches for defining medication use 
in NorPD ( n = 1483) 
Antihypertensive drugs Lipid-lowering drugs Acetylsalicylic acid 
Fixed-time Legend-time, Unit Legend-time, DDD Fixed- time Legend-time, Unit Legend-time, DDD Fixed-time Legend-time, Unit Legend-time, DDD 
Observed agreement ∗, n 1371 1346 1221 1358 1276 1242 1287 1216 1216 
(%) (92.5) (90.8) (82.3) (91.6) (86.0) (82.0) (86.8) (82.0) (82.0) 
Kappa 0.81 0.78 0.62 0.78 0.67 0.63 0.69 0.60 0.60 
(95% CI) (0.78–0.84) (0.74–0.81) (0.58–0.66) (0.74–0.82) (0.63–0.71) (0.55–0.64) (0.65–0.73) (0.55–0.64) (0.55–0.64) 
Both sources, n 1022 982 836 1041 943 910 941 852 852 
(%) (68.9) (66.2) (56.4) (70.2) (63.6) (61.4) (63.5) (57.5) (57.5) 
Tromsø 7 only, n 47 87 233 92 190 223 39 128 128 
(%) (3.2) (5.9) (15.7) (6.2) (12.8) (15.0) (2.6) (8.6) (8.6) 
NorPD only, n 65 50 29 33 17 18 157 139 139 
(%) (4.4) (3.4) (2.0) (2.2) (1.2) (1.2) (10.6) (9.4) (9.4) 
Neither, n 349 364 385 317 333 332 346 364 364 
(%) (23.5) (24.6) (26.0) (21.4) (22.5) (22.4) (23.3) (24.6) (24.6) 
Sensitivity 0.94 0.95 0.97 0.97 0.98 0.98 0.86 0.86 0.86 
(95% CI) (0.92–0.95) (0.94–0.96) (0.95–0.98) (0.96–0.98) (0.97–0.99) (0.97–0.99) (0.84–0.88) (0.84–0.88) (0.84–0.88) 
Specificity 0.88 0.81 0.62 0.78 0.64 0.60 0.90 0.74 0.74 
(95% CI) (0.84–0.91) (0.77–0.84) (0.58–0.66) (0.73–0.81) (0.59–0.68) (0.56–0.64) (0.86–0.93) (0.70–0.78) (0.70–0.78) 
PPV 0.96 0.92 0.78 0.92 0.83 0.80 0.96 0.87 0.87 
(95% CI) (0.94–0.97) (0.90–0.93) (0.76–0.81) (0.90–0.93) (0.81–0.85) (0.78–0.83) (0.95–0.97) (0.85–0.89) (0.85–0.89) 
NPV 0.84 0.88 0.93 0.91 0.95 0.95 0.69 0.72 0.72 
(95% CI) (0.80–0.88) (0.84–0.91) (0.90–0.95) (0.87–0.93) (0.92–0.97) (0.92–0.97) (0.65–0.73) (0.68–0.76) (0.68–0.76) 
∗ Includes agreement of both users and nonusers. 




















Table 3. Self-reported use of statins and different classes of antihypertensive drugs in the Tromsø 7 questionnaire compared with the three approaches for defining medication use in NorPD 
( n = 1483) 

















































Observed agreement ∗, n 1426 1421 1410 1391 1376 1372 1308 1277 1058 1411 1401 1412 1395 1385 1384 1218 1178 1162 
(%) (96.2) (95.9) (95.1) (93.8) (92.8) (92.5) (88.2) (86.1) (71.3) (95.2) (94.5) (95.2) (94.1) (93.4) (93.3) (82.1) (79.4) (78.4) 





































Both sources, n 199 184 174 319 294 292 643 595 309 226 208 215 164 148 147 839 761 742 
(%) (13.4) (12.4) (11.7) (21.5) (19.8) (19.7) (43.4) (40.1) (20.8) (15.2) (14.0) (14.5) (11.1) (10.0) (9.9) (56.6) (51.3) (50.0) 
Tromsø 7 only, n 6 21 31 7 32 34 27 75 361 5 23 16 7 23 24 51 129 148 
(%) (0.4) (1.4) (2.1) (0.5) (2.2) (2.3) (1.8) (5.1) (24.3) (0.3) (1.6) (1.2) (0.5) (1.6) (1.6) (3.4) (8.7) (10.0) 
NorPD only, n 51 41 42 85 75 77 148 131 64 67 59 55 81 75 75 214 176 173 
(%) (3.4) (2.8) (2.8) (5.7) (5.1) (5.2) (10.0) (8.8) (4.3) (4.5) (4.0) (3.7) (5.5) (5.1) (5.1) (14.4) (11.9) (11.7) 
Neither, n 1227 1237 1236 1072 1082 1080 665 682 749 1185 1193 1197 1231 1237 1237 379 417 420 
(%) (82.7) (83.4) (83.4) (72.3) (73.0) (72.8) (44.8) (46.0) (50.5) (79.9) (80.5) (80.7) (83.0) (83.4) (83.4) (25.6) (28.1) (28.3) 




















































































































































∗ Includes agreement of both users and nonusers. 
Abbreviations: ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; CCB, calcium-channel blocker; CI, confidence interval; DDD, defined daily dose; NorPD, Norwegian 
Prescription Database; NPV, negative predictive value; PPV, positive predictive value 






































































































This study demonstrates high agreement between self-
reported use of CHD medications and pharmacy dispens-
ing data among participants with CHD in the seventh wave
of the Tromsø Study. High PPV was shown for all medi-
cations, especially when using a fixed-time window. This
indicates that participants reporting use of such medica-
tions can be presumed to be actual medication-users. Sen-
sitivity and specificity was also found to be high for the
investigated medication classes. This is in accordance with
previous studies [4-7 , 9 , 10 , 12 , 14–16] . 
Negative predictive values were also high for most med-
ication classes, showing that almost all who do not re-
port use of CHD medications are nonusers in NorPD as
well. Lower NPVs for statins and ASA suggest that among
participants not reporting use of these medications, some
have been dispensed such medications. It is possible that
these participants do not actually use statins or ASA, but
it is more likely that they have forgotten to report them in
the questionnaire, thereby being misclassified as nonusers
according to self-report. Predictive values are affected by
prevalence and the high prevalence of use in our study
population contributes to the high PPVs. 
In addition to lower NPV, ASA had a lower kappa-
value, as more participants were classified as ASA-users
by NorPD, and not by Tromsø 7. This was particularly
clear using fixed-time window, where 10.7% of the par-
ticipants were defined as medication-users in NorPD only,
while 2.6% were defined as users only in Tromsø 7. Un-
like for antihypertensive drugs and LLDs, we could only
include those who specified an ASA brand name, and we
would lose users who wrote “blood-thinning medication”.
As this could represent any antithrombotic drug, we could
not include these as ASA-users. We did include answers
to a prespecified question about use of low-dose ASA, but
this question was conditional on a positive answer to a
previous question (“Have you used analgesics and anti-
inflammatory medication regularly in the past year?”). So,
ASA-users did not have the same opportunity as LLD-
/antihypertensive drug-users to report their use, leading to
a likely underestimated agreement for ASA. 
Like ASA, statins had lower agreement and NPV than
the other medication classes. However, the values for all
LLDs combined were higher than for statins alone, es-
pecially when using fixed-time window. Many LLD-users
remember that they use LLDs, but might not report which
type. This again underlines the importance of including
the prespecified question about LLD-use in addition to the
open-ended question when evaluating use of statins. Inter-
estingly, LLDs is the only medication class with a higher
proportion of users defined in Tromsø 7 than in NorPD.
The number of users defined by Tromsø 7 alone is lower
when using a fixed-time window of 365 days, indicating
lower adherence among LLD-users. The lowest sensitivity was found for thiazides, indicat-
ing that the Tromsø 7 questionnaire does not identify all
thiazide-users. Only the open-ended question was used to
define thiazide-users, and we are therefore dependent on
the participants being specific when listing their medica-
tions. In Norway, thiazides are usually sold as part of a
combination product with another antihypertensive drug.
Self-reported use of combination products can be misclas-
sified as single active substances. The thiazide is usually
mentioned at the end of a brand name, e.g. “candesartan
hydrochlorothiazide”, leaving it easy to forget, and result-
ing in lower sensitivity for thiazides. 
The structure of the questions in a questionnaire can af-
fect how a participant reports medication use [25] . A study
by Klungel et al. [2] compared questions about medica-
tions for prespecified conditions with open-ended question
and concluded that prespecified indication alternatives gave
higher recall sensitivity. However, the open-ended ques-
tion and the question with prespecified indications did not
ask about the same medication type. Combining the in-
formation from different types of questions should yield
higher prevalence of medication use [25] . In our study, we
combined prespecified questions and an open-ended ques-
tion. Thereby we could capture participants who forgot to
list some of their medicines in the open-ended question
and participants who use antihypertensive drugs and LLDs
without understanding exactly what the medication is for.
The two questions might lead to different responses as the
prespecified questions ask about current medication use,
while the open-ended one asks about regular use in the last
four weeks. As CHD medications are used chronically, it
is reasonable to assume that both questions would capture
the participants’ recent use of these medications. 
It is not possible to define current use in a prescription
registry in the same way as in a questionnaire. NorPD
states that a medication was dispensed at a certain date
and amount, but not if, when or how the medication was
taken. Two main methods have been used when assess-
ing current medication use in pharmacy records: fixed-time
windows (also called fixed look-back periods) and legend-
time (also called legend-duration or medication-on-hand)
[18] . As there is no consensus on the best method for
defining current medication use in pharmacy records, it
has been recommended to compare different approaches
[18] . We chose to use both fixed-time window and legend-
time methods to define current medication use in NorPD.
A fixed-time window of 180 days was chosen because a
typical dispensing in Norway covers around 90 days of
use, and we added another 90 days to account for poor
adherence and stockpiling. For the same reason we added
10% to the units and DDDs before calculating whether
the dispensed duration would last to the index day when
using the legend-time method [2 , 12 , 15 , 17] . The sensitivity
analyses suggest that this was satisfactory. 


















































































Using one unit compared with one DDD to calculate
legend duration gave similar results for most of the medica-
tion classes. The sensitivity was slightly higher when using
DDDs, while using units generally gave higher agreement,
specificity and PPV. The differences were largest for beta-
blockers. This indicates that the DDD for beta-blockers is
higher than the most commonly prescribed dose of beta-
blockers in Norway. As most of the medications used for
secondary prevention of CHD are used as one unit daily,
this appears to be a better estimate for the prescribed daily
dosage than DDD. The only exception among the medica-
tion classes was calcium-channel blockers, where the DDD
gave slightly higher agreement, sensitivity and PPV than
the unit. This is not unexpected, as some calcium-channel
blockers are recommended to be taken more than once a
day. 
We used NorPD as the reference standard in calculat-
ing our validity measures. NorPD can be considered more
reliable than self-report as the registry has complete cov-
erage of dispensed medications used for secondary pre-
vention of CHD. These medications are also not available
over-the-counter in Norway. Using dispensing data as the
reference standard is common in validation studies [4–
6 , 9 , 10] . However, the choice of definition matters, and
careful considerations are needed when choosing fixed-
time or legend-time, and dosage unit or DDD as unit of
use. We found that for CHD medications used chronically,
a fixed-time window of 180 days gave the best results
with higher values of both percent agreement and kappa
as well as higher specificity and PPV for all medications.
Though sensitivity and NPV was higher for most medi-
cations when using the legend-time methods, the differ-
ences from fixed-time window were small. The fixed-time
window is also more easily applicable than the legend-
time method. Overall, using a fixed-time window could be
recommended for most studies investigating use of these
medications. For other medication classes this might be
different. 
5. Conclusion 
Self-reported information on current use of medications
for secondary prevention of coronary heart disease col-
lected with a questionnaire combining prespecified and
open-ended questions shows high validity compared with
pharmacy dispensing data. Though a combination with dis-
pensing data is preferable, this questionnaire provides a
sufficiently accurate classification of such medication ex-
posure should prescription data be unavailable. 
Validity and agreement measures varied depending on
the definition of medication use in NorPD. For CHD medi-
cations, using a fixed-time window gave better results than
the legend-time methods. However, this may vary depend-
ing on medication class, setting and data source. Funding 
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